<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Gastric acid is believed to be an important etiological factor in the pathogenesis of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Pulsatile acid exposure increases cell proliferation in ex vivo Barrrett's tissue and normalization of esophageal pH reverses this </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="49200">Proton pump inhibitors</z:chebi> (<z:chebi fb="4" ids="53266">PPIs</z:chebi>) are the mainstay of therapy in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>, and have numerous beneficial effects including symptom control, reduction of <z:mp ids='MP_0001845'>inflammation</z:mp>, and promotion of the development of squamous islands </plain></SENT>
<SENT sid="3" pm="."><plain>However, <z:chebi fb="4" ids="53266">PPI</z:chebi> therapy causes hypergastrinemia and has not prevented recent increase in the incidences of <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Additionally, evidence presented here by Feagins et al. suggests that acid exposure has a p53-mediated, antiproliferative effect on a nondysplastic Barrett's epithelial cell line, an effect that acid suppression might abrogate </plain></SENT>
<SENT sid="5" pm="."><plain>These complex pH, <z:mp ids='MP_0001845'>inflammation</z:mp>, and growth factor biological interactions can be most reliably tested in large clinical trials with hard end points like <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> conversion or <z:hpo ids='HP_0000001'>all</z:hpo> causes of mortality </plain></SENT>
<SENT sid="6" pm="."><plain>Combining the anti-inflammatory effects of acid suppression with aspirin, a <z:chebi fb="0" ids="35475">nonsteroidal anti-inflammatory agent</z:chebi>, is the subject of the AspECT clinical trial, and this may be the future of chemoprevention in Barrett's </plain></SENT>
</text></document>